Doctor Bio:
Dr. Xavier Leleu is Professor, Head of the Myeloma Clinic and Head of the Department of Haematology at Hôpital La Mileterie, part of the academic hospital of Poitiers (Centre Hospitalier Universitaire) in Poitiers, France.
Phase 2 Study IFM 2018-02 (I-Dara) Presented at ASCO 2022
Dr. Xavier Leleu Discusses Phase 2 Study IFM 2018-02 (I-Dara) in Elderly Frail RRMM Patients
Abstract title:
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail relapsed/refractory multiple myeloma (RRMM) patients: A multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
In this video:
Dr. Xavier Leleu (Centre Hospitalier Universitaire—Poitiers, France) explains the results of the Phase 2 Study IFM 2018-02 (I-Dara) in elderly frail relapsed/refractory multiple myeloma (RRMM) patients.
What is the purpose of this trial?
The aim of this phase 2 study is to evaluate the efficacy and tolerability of ixazomib-daratumumab (I-Dara) without dexamethasone in elderly frail patients with relapsed/refractory multiple myeloma (RRMM).
Conclusion:
In this elderly frail population, ixazomib-daratumumab (I-Dara) is a feasible combination with favorable efficacy profile even in lenalidomide RRM and HR cytogenetic patients. Early toxicity remains a concern in this population, even though more manageable with subcutaneous daratumumab.
Clinical trial information: NCT03757221
with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology
